Lung Cancer |

A Retrospective Study Reviewing Treatment Patterns of Patients With Lung Cancer FREE TO VIEW

Thomas Gildea, MD; Jed Gorden; David Wilson, MD; Douglas Hogarth, MD; Stacey DaCosta Byfield; Curtis Quinn, MD
Author and Funding Information

The Cleveland Clinic, Cleveland, OH

Chest. 2015;148(4_MeetingAbstracts):588A. doi:10.1378/chest.2280507
Text Size: A A A
Published online


SESSION TITLE: Lung Cancer Treatment Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: Delays in the diagnosis of lung cancer can lead to identification of the disease at later stages creating missed treatment opportunities which likely result in worse outcomes and higher costs of care. However, few studies examine delays to definitive diagnosis of lung cancer or estimate costs prior to definitive lung cancer diagnosis.

METHODS: Adult patients diagnosed with lung cancer between 01 January 2007 and 30 September 2011 were identified from a proprietary oncology registry and linked with health insurance claims from a large US health insurance company and social security mortality data. Patients were required to have at least 12 months of continuous enrollment in the health plan prior to lung cancer diagnosis (baseline) and at least 3 months of continuous enrollment after diagnosis (follow-up); patients with less than 3 months of follow-up due to death were included in the study. Use of diagnostic tests and time to diagnosis was examined. Rates of healthcare utilization and per-patient per-month (PPPM) healthcare costs were calculated.

RESULTS: Most patients (≈94%) had evidence of diagnostic tests beginning 5 to 6 months prior to diagnosis. In general, patients diagnosed with earlier stages of disease had lower rates of healthcare utilization. The mean PPPM total healthcare costs pre- and post-diagnosis were $2,407 (standard deviation (SD) = $3,364) and $16,577 (SD = $33,550) respectively. PPPM total healthcare costs after lung cancer diagnosis were highest among patients diagnosed with Stage IV disease at $21,441 (SD = $29,777) and lowest among patients diagnosed with Stage I disease at $7,239 (SD = $7,611).

CONCLUSIONS: Patients involved in this study experienced long periods of delay between their first diagnostic test for lung cancer and a definitive diagnosis. As shown in previous studies, our current data demonstrates costs associated with management of lung cancer increase with higher stages at diagnosis.

CLINICAL IMPLICATIONS: Procedures that diagnose lung cancer at earlier stages may allow for less resource use and costs among patients with lung cancer.

DISCLOSURE: Thomas Gildea: Consultant fee, speaker bureau, advisory committee, etc.: Covidien- SAB and international Education Jed Gorden: Consultant fee, speaker bureau, advisory committee, etc.: Covidien- SAB David Wilson: Consultant fee, speaker bureau, advisory committee, etc.: Covidien- SAB Douglas Hogarth: Consultant fee, speaker bureau, advisory committee, etc.: Covidien- SAB Curtis Quinn: Consultant fee, speaker bureau, advisory committee, etc.: Covidien- SAB The following authors have nothing to disclose: Stacey DaCosta Byfield

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543